Prospects of vaccines for medically important fungi. Feasibility and prospects for a vaccine to prevent cryptococcosis

Medical Mycology

Volumn 43, Issue 8, 2005, Pages 667-680

  Casadevall, Arturo ^a   Pirofski, Liise Anne ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cryptococcosis; Cryptococcus neoformans; Vaccine development

Indexed keywords

ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CERAMIDE DERIVATIVE; CORTICOSTEROID DERIVATIVE; DIPHTHERIA TOXOID; FUNGUS ANTIGEN; FUNGUS VACCINE; GAMMA INTERFERON; GLUCURONOXYLOMANNAN; IMMUNOSUPPRESSIVE AGENT; INACTIVATED VACCINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPID; LIVE VACCINE; MANNOPROTEIN; MELANIN; MONOCLONAL ANTIBODY; PIGMENT; POLYSACCHARIDE; SUBUNIT VACCINE; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELLULAR IMMUNITY; CLINICAL TRIAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE ASSOCIATION; DRUG DESIGN; ECONOMIC ASPECT; EPIDEMIC; FEASIBILITY STUDY; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; INFLAMMATORY DISEASE; INNATE IMMUNITY; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PROSPECTIVE STUDY; REVIEW; SPECIES DIFFERENCE; VACCINATION; ANIMAL; DISEASE MODEL; ECONOMICS; IMMUNOLOGY;

ANIMALIA; FILOBASIDIELLA NEOFORMANS; FUNGI; HUMAN IMMUNODEFICIENCY VIRUS;

ANIMALS; ANTIGENS, FUNGAL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; FUNGAL VACCINES; HUMANS; VACCINATION;

EID: 33644796922     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.1080/13693780500448230     Document Type: Review

References (141)

1. Gadebusch, HH. (1958) Active immunization against Cryptococcus neoformans J Infect Dis, 102, pp. 219 - 226.
2. Goren, MB. (1967) Experimental murine cryptococcosis: Effect of hyperimmunization to capsular polysaccharide J Immunol, 98, pp. 914 - 922.
3. Goren, MB and Middlebrook, GM. (1967) Protein conjugates of polysaccharide from Cryptococcus neoformans J Immunol, 98, pp. 901 - 913.
4. Reiss, F and Werber-Alture, E. (1976) Immunization of mice with a mutant of Cryptococcus neoformans Dermatologica, 152, pp. 16 - 22.
5. Segal, E. (1987) Vaccines against fungal infections CRC Crit Rev Microbiol, 14, pp. 229 - 273.
6. Polonelli, L and Casadevall, A and Han, Y and (2000) The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections Med Mycol, 38(Suppl. 1), pp. 281 - 292.
7. Deepe, GS, Jr. (1997) Prospects for the development of fungal vaccines Clin Microbiol Rev, 10, pp. 585 - 596.
8. Deepe, GS, Jr. (2004) Preventative and therapeutic vaccines for fungal infections: From concept to implementation Expert Rev Vaccines, 3, pp. 701 - 709.
9. Pirofski, L. (2001) Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens Trends Microbiol, 9, pp. 445 - 451.
10. Dixon, DM and Casadevall, A and Klein, B and (1998) Development of vaccines and their use in the prevention of fungal infections Med Mycol, 36((Suppl.)), pp. 57 - 67.
11. Casadevall, A and Perfect, JR.(1998) Cryptococcus neoformans. Washington DC: American Society for Microbiology.
12. Mitchell, TG and Perfect, JR. (1995) Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans Clin Microbiol Rev, 8, pp. 515 - 548.
13. Currie, BP and Casadevall, A. (1994) Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City Clin Infect Dis, 19, pp. 1029 - 1033.
14. Lortholary, O and Fontanet, A and Memain, N and (2005) Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France AIDS, 19, pp. 1043 - 1049.
15. Jenny-Avital, ER and Abadi, M. (2002) Immune reconstitution syndrome after initiation of successful highly active antiretroviral therapy Clin Infect Dis, 15, pp. e128 - 133.
16. Shelburne, SA and Darcourt, III and White, AC, Jr and (2005) The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy Clin Infect Dis, 40, pp. 1049 - 1052.
17. French, N and Gray, K and Watera, C and (2002) Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults AIDS, 16, pp. 1031 - 1038.
18. Banerjee, U and Datta, K and Majumdar, T and (2001) Cryptococcosis in India: The awakening of a giant? Med Mycol, 39, pp. 51 - 67.
19. Husain, S and Wagener, MM and Singh, N. (2001) Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome Emerg Infect Dis, 7, pp. 375 - 381.
20. Shrestha, RK and Stoller, JK and Honari, G and (2004) Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: Possible zoonotic transmission from a pet cockatiel Respir Care, 49, pp. 606 - 608.
21. Tabone, MD and Leverger, G and Landman, J and (1994) Disseminated lymphonodular cryptococcosis in a child with X-linked hyper-IgM immunodeficiency Pediatr Infect Dis J, 13, pp. 77 - 79.
22. Winkelstein, JA and Marino, MC and Ochs, H and (2003) The X-linked hyper-IgM syndrome: Clinical and immunologic features of 79 patients Medicine (Baltimore), 82, pp. 373 - 384.
23. Gupta, S and Ellis, M and Cesario, T and (1987) Disseminated cryptococcal infection in a patient with hypogammaglobulinemia and normal T-cell function Am J Med, 82, pp. 129 - 131.
24. Neto, RJ and Guimaraes, MC and Moya, MJ and (2000) Hypogammaglobulinemia as risk factor for Cryptococcus neoformans infection: Report of 2 cases Rev Soc Bras Med Trop, 33, pp. 603 - 608.
25. Melzer, M and Colbridge, M and Keenan, F and (1998) Cryptococcosis: An unusual opportunistic infection complicating B cell lymphoproliferative disorders J Infect, 36, pp. 220 - 222.
26. Kaplan, MH and Roses, PP and Armstrong, D. (1977) Cryptococcosis in a cancer hospital. Clinical and pathological correlates in forty-six patients Cancer, 39, pp. 2265 - 2274.
27. Goldman, DL and Khine, H and Abadi, J and (2001) Serologic evidence for Cryptococcus infection in early childhood Pediatrics, 107, pp. E66.
28. Abadi, J and Nachman, S and Kressel, AB and (1999) Cryptococcosis in children with AIDS Clin Infect Dis, 28, pp. 309 - 313.
29. Abadi, J and Pirofski, L. (1999) Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without HIV infection J Infect Dis, 180, pp. 915 - 919.
30. Chen, L-C and Goldman, DL and Doering, TL and (1999) Antibody response to Cryptococcus neoformans proteins in rodents and humans Infect Immun, 67, pp. 2218 - 2224.
31. DeShaw, M and Pirofski, L-A. (1995) Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV - individuals Clin Exp Immunol, 99, pp. 425 - 432.
32. Dromer, F and Aucouturier, P and Clauvel, J-P and (1988) Cryptococcus neoformans antibody levels in patients with AIDS Scan J Infect Dis, 20, pp. 283 - 285.
33. Arora, S and Huffnagle, GB. (2005) Immune regulation during allergic bronchopulmonary mycosis: Lessons taught by two fungi Immunol Res, 33, pp. 53 - 68.
34. Franzot, SP and Salkin, IF and Casadevall, A. (1999) Cryptococcus neoformans var. grubii: Separate variety status for Cryptococcus neoformans serotype A isolates J Clin Microbiol, 37, pp. 838 - 840.
35. Sorrell, TC. (2001) Cryptococcus neoformans variety gattii Med Mycol, 39, pp. 155 - 168.
36. Loftus, BJ and Fung, E and Roncaglia, P and (2005) The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans Science, 307, pp. 1321 - 1324.
37. Kidd, SE and Hagen, F and Tscharke, RL and (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada) Proc Natl Acad Sci USA, 101, pp. 17258 - 17263.
38. Colom, MF and Frases, S and Ferrer, C and (2005) First case of human cryptococcosis due to Cryptococcus neoformans var. gattii in Spain J Clin Microbiol, 43, pp. 3548 - 3550.
39. Nosanchuk, JD and Shoham, S and Fries, BC and (2000) Evidence for zoonotic transmission of Cryptococcus neoformans from a pet cockatoo to an immunocompromised patient Ann Intern Med, 132, pp. 205 - 208.
40. Fessel, WJ. (1993) Cryptococcal meningitis after unusual exposures to birds N Engl J Med, 328, pp. 1354 - 1355.
41. Garcia-Hermoso, D and Janbon, G and Dromer, F. (1999) Epidemiological evidence for dormant Cryptococcus neoformans infection J Clin Microbiol, 37, pp. 3204 - 3209.
42. Baker, RD. (1976) The primary pulmonary lymph node complex of cryptococcosis Am J Clin Pathol, 65, pp. 83 - 92.
43. Singh, N and Lortholary, O and Alexander, BD and (2005) An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients Clin Infect Dis, 40, pp. 1756 - 1761.
44. Goldman, DL and Lee, SC and Mednic, AJ and (2000) Persistent Cryptococcus neoformans infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression and altered antibody responsiveness Infect Immun, 68, pp. 832 - 838.
45. Oxman, MN and Levin, MJ and Johnson, GR and (2005) Avaccine to prevent herpes zoster and postherpetic neuralgia in older adults N Engl J Med, 352, pp. 2271 - 2284.
46. Casadevall, A and Pirofski, L. (2003) The damage-response framework of microbial pathogenesis Nature Microbiol Rev, 1, pp. 17 - 24.
47. Chen, S and Sorrell, T and Nimmo, G and (2000) Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group Clin Infect Dis, 31, pp. 499 - 508.
48. Murphy, JW. (1992) Cryptococcal immunity and immunostimulation Adv Exp Med Biol, 319, pp. 225 - 230.
49. Murphy, JW. (1998) Protective cell-mediated immunity against Cryptococcus neoformans Res Immunol, 149, pp. 373 - 386.
50. Huffnagle, GB and Lipscomb, MF. (1998) Cells and cytokines in pulmonary cryptococcosis Res Immunol, 149, pp. 387 - 396.
51. Perfect, JR and Casadevall, A. (2002) Cryptococcosis Infect Dis Clin North Am, 16, pp. 837 - 874.
52. Goldman, D and Lee, SC and Casadevall, A. (1994) Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat Infect Immun, 62, pp. 4755 - 4761.
53. Huffnagle, GB and Yates, JL and Lipscomb, MF. (1991) T cell-mediated immunity in the lung: A Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice Infect Immun, 59, pp. 1423 - 1433.
54. Casadevall, A. (1995) Antibody immunity and invasive fungal infections Infect Immun, 63, pp. 4211 - 4218.
55. Feldmesser, M and Kress, Y and Novikoff, P and (2000) Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection Infect Immun, 68, pp. 4225 - 4237.
56. Fleuridor, R and Lyles, RH and Pirofski, L. (1999) Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis J Infect Dis, 180, pp. 1526 - 1535.
57. Maitta, R and Datta, K and Chang, Q and (2004) Protective and non-protective human IgM monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan manifest different specificity and gene usage Infect Immun, 22, pp. 4062 - 4068.
58. Maitta, R and Datta, K and Lees, A and (2003) Immunogenicity and efficacy of cryptococcal glucuronoxylomannan peptide mimotope-protein conjugates in human immunoglobulin transgenic mice Infect Immun, 72, pp. 196 - 208.
59. Shao, X and Mednick, A and Alvarez, M and (2005) An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia J Immunol, 175, pp. 3244 - 3251.
60. Mednick, AJ and Feldmesser, M and Rivera, J and (2003) Neutropenia alters lung cytokine production in mice and reduces their susceptibility to pulmonary cryptococcosis Eur J Immunol, 33, pp. 1744 - 1753.
61. Casadevall, A and Feldmesser, M and Pirofski, L. (2002) Induced humoral immunity and vaccination against major human fungal pathogens Curr Opin Microbiol, 5, pp. 386.
62. Casadevall, A and Pirofski, L. (2005) Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans Curr Mol Med, 5, pp. 421 - 433.
63. Dromer, F and Charreire, J and Contrepois, A and (1987) Protection of mice against experimental cryptococcosis by anti-Cryptococcus neoformans monoclonal antibody Infect Immun, 55, pp. 749 - 752.
64. Sanford, JE and Lupan, DM and Schlagetter, AM and (1990) Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide Infect Immun, 58, pp. 1919 - 1923.
65. Mukherjee, J and Scharff, MD and Casadevall, A. (1992) Protective murine monoclonal antibodies to Cryptococcus neoformans Infect Immun, 60, pp. 4534 - 4541.
66. Fleuridor, R and Zhong, Z and Pirofski, L. (1998) A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis J Infect Dis, 178, pp. 1213 - 1216.
67. Aguirre, KM and Johnson, LL. (1997) A role for B cells in resistance to Cryptococcus neoformans in mice Infect Immun, 65, pp. 525 - 530.
68. Rivera, J and Zaragoza, O and Casadevall, A. (2005) Antibody-mediated protection against Cryptococcus neoformans is dependent on B cells Infect Immun, 73, pp. 1141 - 1150.
69. Devi, SJN. (1996) Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model Vaccine, 14, pp. 841 - 842.
70. Fleuridor, R and Lees, A and Pirofski, L. (2001) A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection J Immunol, 166, pp. 1087 - 1096.
71. Parra, C and Gonzalez, JM and Castaneda, E and (2005) Anti-glucuronoxylomannan IgG1 specific antibodies production in Cryptococcus neoformans resistant mice Biomedica, 25, pp. 110 - 119.
72. Vecchiarelli, A. (2005) The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies Curr Mol Med, 5, pp. 413 - 420.
73. Vecchiarelli, A and Casadevall, A. (1998) Antibody-mediated effects against Cryptococcus neoformans: Evidence for interdependency and collaboration between humoral and cellular immunity Res Immunol, 149, pp. 321 - 333.
74. Vecchiarelli, A. (2000) Immunoregulation by capsular components of Cryptococcus neoformans Med Mycol, 38, pp. 407 - 417.
75. Rivera, J and Mukherjee, J and Weiss, LM and (2002) Antibody efficacy in murine pulmonary Cryptococcus neoformans infection: A role for nitric oxide J Immunol, 168, pp. 3419 - 3427.
76. Rivera, J and Casadevall, A. (2005) Mouse genetic background is a major determinant of isotype-related differences for antibody-mediated protective efficacy against Cryptococcus neoformans J Immunol, 174, pp. 8017 - 8026.
77. Cherniak, R and Sundstrom, JB. (1994) Polysaccharide antigens of the capsule of Cryptococcus neoformans Infect Immun, 62, pp. 1507 - 1512.
78. Murphy, JW and Cozad, GC. (1972) Immunological unresponsiveness induced by cryptococcal polysaccharide assayed by the hemolytic plaque technique Infect Immun, 5, pp. 896 - 901.
79. Kozel, TR and Gulley, WF and Cazin, JJ. (1977) Immune response to Cryptococcus neoformans soluble polysaccharide: Immunological unresponsiveness Infect Immun, 18, pp. 701 - 707.
80. Casadevall, A and Mukherjee, J and Devi, SJN and (1992) Antibodies elicited by a Cryptococcus neoformans glucuronoxylomannan-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection J Infect Dis, 65, pp. 1086 - 1093.
81. Devi, SJN and Schneerson, R and Egan, W and (1991) Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity Infect Immun, 59, pp. 3700 - 3707.
82. Oscarson, S and Alpe, M and Svahnberg, P and (2005) Synthesis and immunological studies of glycoconjugates of Cryptococcus neoformans capsular glucuronoxylomannan oligosaccharide structures Vaccine, 23, pp. 3961 - 3972.
83. Kakeya, H and Udono, H and Ikuno, N and (1997) A 77-kilodalton protein of Cryptococcus neoformans a member of the heat shock protein 70 family, is a major antigen detected in the sera of mice with pulmonary cryptococcosis Infect Immun, 65, pp. 1653 - 1658.
84. Chen, L-C and Pirofski, L and Casadevall, A. (1997) Extracellular proteins of Cryptococcus neoformans and host antibody response Infect Immun, 65, pp. 2599 - 2605.
85. Murphy, JW and Mosley, RL and Cherniak, R and (1988) Serological, electrophoretic, and biological properties of Cryptococcus neoformans antigens Infect Immun, 56, pp. 424 - 431.
86. Buchanan, KL and Murphy, JW. (1993) Characterization of cellular infiltrates and cytokine production during the expression of athe anticryptococcal delayed-type hypersensitivity response Infect Immun, 61, pp. 2854 - 2865.
87. Murphy, JW and Shafer, F and Casadevall, A and (1998) Antigen-induced protective and non-protective cell-mediated immune components against Cryptococcus neoformans Infect Immun, 66, pp. 2632 - 2639.
88. Muth, SM and Murphy, JW. (1995) Effects of immunization with Cryptococcus neoformans cells or cryptococcal culture filtrate antigen on direct anticryptococcal activities of murine T lymphocytes Infect Immun, 63, pp. 1645 - 1651.
89. Uicker, WC and Doyle, HA and McCracken, JP and (2005) Cytokine and chemokine expression in the central nervous system associated with protective cell-mediated immunity against Cryptococcus neoformans Med Mycol, 43, pp. 27 - 38.
90. Mandel, MA and Grace, GG and Orsborn, KI and (2000) The Cryptococcus neoformans gene DHA1 encodes an antigen that elicits a delayed-type hypersensitivity reaction in immune mice Infect Immun, 68, pp. 6196 - 6201.
91. Biondo, C and Beninati, C and Delfino, D and (2002) Identification and cloning of a cryptococcal deacetylase that produces protective immune responses Infect Immun, 70, pp. 2383 - 2391.
92. Biondo, C and Beninati, C and Bombaci, M and (2003) Induction of T helper type 1 responses by a polysaccharide deacetylase from Cryptococcus neoformans Infect Immun, 71, pp. 5412 - 5417.
93. Levitz, SM and Nong, S and Mansour, MK and (2001) Molecular characterization of a mannoprotein with homology to chitin deacetylases that stimulates T cell responses to Cryptococcus neoformans Proc Natl Acad Sci USA, 98, pp. 10422 - 10427.
94. Huang, C and Nong, SH and Mansour, MK and (2002) Purification and characterization of a second immunoreactive mannoprotein from Cryptococcus neoformans that stimulates T-Cell responses Infect Immun, 70, pp. 5485 - 5493.
95. Mansour, MK and Schlesinger, LS and Levitz, SM. (2002) Optimal T cell responses to Cryptococcus neoformans mannoprotein are dependent on recognition of conjugated carbohydrates by mannose receptors J Immunol, 168, pp. 2872 - 2879.
96. Pietrella, D and Cherniak, R and Strappini, C and (2001) Role of mannoprotein in induction and regulation of immunity to Cryptococcus neoformans Infect Immun, 69, pp. 2808 - 2810.
97. Rodrigues, ML and Travassos, LR and Miranda, KR and (2000) Human antibodies against a purified glucosylceramide from Cryptococcus neoformans inhibit cell budding and fungal growth Infect Immun, 68, pp. 7049 - 7060.
98. Rosas, AL and Nosanchuk, JD and Casadevall, A. (2001) Passive immunization with melanin-binding monoclonal antibodies prolongs survival in mice with lethal Cryptococcus neoformans infection Infect Immun, 69, pp. 3410 - 3412.
99. McClelland, EE and Granger, DL and Potts, WK. (2003) Major histocompatibility complex-dependent susceptibility to Cryptococcus neoformans in mice Infect Immun, 71, pp. 4815 - 4817.
100. Dromer, F and Yeni, P and Charreire, J. (1988) Genetic control of the humoral response to cryptococcal capsular polysaccharide in mice Immunogenetics, 28, pp. 417 - 424.
101. Beenhouwer, DO and Shapiro, S and Feldmesser, M and (2001) Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans Infect Immun, 69, pp. 6445 - 6455.
102. Yuan, R and Casadevall, A and Spira, G and (1995) Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody J Immunol, 154, pp. 1810 - 1816.
103. Yuan, R and Spira, G and Oh, J and (1998) Isotype switching increases antibody protective efficacy to Cryptococcus neoformans infection in mice Infect Immun, 66, pp. 1057 - 1062.
104. Yuan, R and Casadevall, A and Oh, J and (1997) T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice Proc Natl Acad Sci USA, 94, pp. 2483 - 2488.
105. Goldman, DL and Casadevall, A and Cho, Y and (1996) Cryptococcus neoformans meningitis in the rat Lab Invest, 75, pp. 759 - 770.
106. Perfect, JR and Lang, SDR and Durack, DT. (1980) Chronic cryptococcal meningitis Am J Path, 101, pp. 177 - 193.
107. Fromtling, RA and Blackstock, R and Hall, NK and (1979) Immunization of mice with an avirulent pseudohyphal form of Cryptococcus neoformans Mycopathologia, 68, pp. 179 - 181.
108. Pirofski, L and Casadevall, A. (1998) The use of licensed vaccines for active immunization of the immunocompromised host Clin Microbiol Rev, 11, pp. 1 - 26.
109. Louria, DB. (1960) Specific and non-specifc immunity in experimental cryptococcosis in mice J Exp Med, 111, pp. 643 - 665.
110. Granger, DL and Perfect, JR and Durack, DT. (1986) Macrophage-mediated fungistosis in vitro: Requirements for intracellular and extracellular toxicity J Immunol, 136, pp. 672 - 680.
111. Walzl, G and Humphreys, IR and Marshall, BG and (2003) Prior exposure to live Mycobacterium bovis BCG decreases Cryptococcus neoformans-induced lung eosinophilia in a gamma interferon-dependent manner Infect Immun, 71, pp. 3384 - 3391.
112. Blackstock, R and McElwee, N and Neller, E and (2000) Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM), associated with peritoneal antigen-presenting cells (APC): Requirements for GXM, APC activation, and interleukin-12 Infect Immun, 68, pp. 5146 - 5153.
113. Blackstock, R and Casadevall, A. (1997) Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival Immunology, 92, pp. 334 - 339.
114. Blackstock, R and McElwee, N and Neller, E and (2000) Regulation of cytokine expression in mice immunized with cryptococcal polysaccharide, a glucuronoxylomannan (GXM0, associated with peritoneal antigen-presenting cells (APC): Requirements for APC, APC activation and interleukin-12 Infect Immun, 68, pp. 5146 - 5153.
115. Muth, SM and Murphy, JW. (1995) Direct anticryptococcal activity of lymphocytes from Cryptococcus neoformans-immunized mice Infect Immun, 63, pp. 1637 - 1644.
116. Mansour, MK and Yauch, LE and Rottman, JB and (2004) Protective efficacy of antigenic fractions in mouse models of cryptococcosis Infect Immun, 72, pp. 1746 - 1754.
117. Murphy, JW. (1988) Influence of cryptococcal antigens on cell-mediated immunity Rev Infect Dis, 10(Suppl. 2), pp. S432 - S435.
118. Mukherjee, J and Nussbaum, G and Scharff, MD and (1995) Protective and non-protective monoclonal antibodies to Cryptococcus neoformans originating from one B-cell J Exp Med, 181, pp. 405 - 409.
119. Mukherjee, J and Casadevall, A and Scharff, MD. (1993) Molecular characterization of the antibody responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization J Exp Med, 177, pp. 1105 - 1106.
120. Nussbaum, G and Anandasabapathy, S and Mukherjee, J and (1999) Molecular and idiotypic analysis of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and non-autoimmune mice Infect Immun, 67, pp. 4469 - 4467.
121. Spoljar, BH and Tomasic, J. (2000) A novel ELISA for determination of polysaccharide specific immunoglobulins Vaccine, 19, pp. 924 - 930.
122. Shapiro, S and Beenhouwer, DO and Feldmesser, M and (2002) Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3 Infect Immun, 70, pp. 2598 - 2604.
123. Williamson, PR and Bennett, JE and Polis, MA and (1993) Immunogenicity and safety of a conjugate glucuronoxylomannan-tetanus conjugate vaccine in volunteers Clin Infect Dis, 17, pp. 540. [Abstract 56]
124. Maitta, RW and Datta, K and Pirofski, LA. (2004) Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan Vaccine, 22, pp. 4062 - 4068.
125. Subramaniam, KS and French, N and Pirofski, L. (2005) Cryptococcus neoformans-reactive and total immunoglobulin profiles of human immunodeficiency virus-infected and uninfected Ugandans Clin Diagn Lab Immunol, 12, pp. 1168 - 1176.
126. Houpt, DC and Pfrommer, GST and Young, BJ and (1994) Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuronoxylomannan Infect Immun, 62, pp. 3857 - 2864.
127. Taborda, CP and Casadevall, A. (2001) Immunoglobulin M efficacy against Cryptococcus neoformans: Mechanism, dose dependence and prozone-like effects in passive protection experiments J Immunol, 66, pp. 2100 - 2107.
128. Taborda, CP and Rivera, J and Zaragoza, O and (2003) More is not necessarily better: 'Prozone-like' effects in passive immunization with Immunoglobulin G J Immunol, 140, pp. 3621 - 3630.
129. Pirofski, L and Lui, R and DeShaw, M and (1995) Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine Infect Immun, 63, pp. 3005 - 3014.
130. Zhang, H and Zhong, Z and Pirofski, L. (1997) Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody Infect Immun, 65, pp. 1158 - 1164.
131. Chang, Q and Abadi, J and Alpert, P and (2000) A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons J Infect Dis, 181, pp. 1313 - 1321.
132. Zhong, Z and Pirofski, L. (1996) Opsonization of Cryptococcus neoformans by human anti-glucuronoxylomannanantibodies Infect Immun, 64, pp. 3446 - 3450.
133. Valadon, P and Nussbaum, G and Oh, J and (1998) Aspects of antigen mimicry revealed by immunization with a peptide mimetic of Cryptococcus neoformans polysaccharide J Immunol, 161, pp. 1829 - 1836.
134. Nakouzi, A and Casadevall, A. (2003) The function of conserved amino acids at or near the complementarity determining regions for related antibodies to Cryptococcus neoformans glucuronoxylomannan Mol Immunol, 40, pp. 351 - 361.
135. Beenhouwer, DO and Valadon, P and May, R and Scharff, MD.(2000) Peptide mimicry of the polysaccharide capsule of Cryptococcus neoformans. In Molecular mimicry, microbes and autoimmunity. (pp. 143 - 160). Washington: ASM Press.
136. May, RJ and Beenhouwer, DO and Scharff, MD. (2003) Antibodies to keyhole limpet hemocyanin cross-react with an epitope on the polysaccharide capsule of Cryptococcus neoformans and other carbohydrates: Implications for vaccine development J Immunol, 171, pp. 4905 - 4912.
137. Edwards, L and Williams, AE and Krieg, AM and (2005) Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner Eur J Immunol, 35, pp. 273 - 281.
138. Miyagi, K and Kawakami, K and Kinjo, Y and (2005) CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells Clin Exp Immunol, 140, pp. 220 - 229.
139. Banerjee, B and Kelly, KJ and Fink, JN and (2004) Modulation of airway inflammation by immunostimulatory CpG oligodeoxynucleotides in a murine model of allergic aspergillosis Infect Immun, 72, pp. 6087 - 6094.
140. Lutz, JE and Clemons, KV and Stevens, DA. (2000) Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis J Antimicrob Chemother, 46, pp. 437 - 442.
141. Williams, AE and Humphreys, IR and Cornere, M and (2005) TGF-beta prevents eosinophilic lung disease but impairs pathogen clearance Microbes Infect, 7, pp. 365 - 374.